Our Blog: To Your Health

The Oregon Clinic Now Offers eConsults for Providers

Thursday, April 30, 2020


When it comes to your health, we want to make sure you’re receiving the best quality care possible. That includes working with your other healthcare providers to make communicating about your care as easy and convenient as possible.

That’s why The Oregon Clinic is excited to now offer eConsults to primary care providers and other specialists.

eConsults are an easy and convenient way for healthcare providers to access to our Board-Certified specialist doctors as we find new ways to work together remotely.

The Oregon Clinic Offers Virtual Visits for Patients in Response to COVID-19

Friday, April 17, 2020

In response to the COVID-19 pandemic, the specialty physicians at The Oregon Clinic are now offering virtual health visits to many patients. With Oregon and Southwest Washington residents asked to stay home and restricted from visiting physicians for non-urgent appointments, many patients have been unable to access necessary specialist health care.

Colon Cancer Screening: A Modern-Day Medical Success Story in The Making

Friday, March 13, 2020
Colon cancer remains a common and deadly cancer—it is the second most common cause of cancer death in men and women in the United States, affecting approximately four percent of people in their lifetimes.
In the past 50 years, we have seen dramatic improvements in survival rates and a decline in the incidence of colon cancer in those older than 50. In fact, survival rates from colon cancer have improved by two percent per year in recent decades, cutting the mortality rate in half since 1970.

Considering the Risks and Benefits of Proton Pump Inhibitor Use

Friday, March 6, 2020

Proton pump inhibitors (PPIs; e.g. Prilosec/omeprazole, Prevacid/lansoprazole, and others) are among the most commonly used medications, with prevalence estimates ranging between about five percent and fifteen percent of the adult population. Recently, there have been increasing concerns about the safety of long-term PPI use, leading many patients to abandon their PPIs in favor of H2 receptor antagonists (H2RAs; e.g. Pepcid/famotidine, Zantac/ranitidine, Tagamet/cimetidine) or to stop acid suppression therapy altogether. While the tenet of “first, do no harm” remains paramount in the practice of medicine, it is important to use caution when interpreting reports of risks associated with PPI use.